Experimental and clinical trials have evaluated small-molecule inhibitors, monoclonal antibodies, and multi-target inhibitors targeting pathways including TGF-β, Wnt, VEGFR, and EGFR, as well as key molecules like AKT, KRAS, and COX-2, to suppress EMT in CRC [137–145]. This evidence concerns the gene TGFB1 and colorectal carcinoma.